Zydus Lifesciences Limited announced that it has successfully received the Establishment Inspection Report (EIR) and the official approval letter from the USFDA. This approval follows the Pre-Approval Inspection (PAI) conducted at the company's oncology injectable manufacturing site located in SEZ1, Ahmedabad.
The successful inspection confirms the readiness of the facility, specifically relating to the company's new isolator injectable line. The USFDA conducted the Pre-Approval Inspection from November 4 to November 13, 2025.
The announcement of this key operational milestone was made on April 16, 2026.
ZYDUSLIFE Stock Price Movement
As of 12:52 PM, shares of Zydus Lifesciences Limited are slipping by 0.24% in live trading, currently trading at ₹933.85. The stock has seen active intraday movement, with 308,202 shares traded, keeping it contained within the day's range of ₹930.2 to ₹948.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.